Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

PrEP policies and guidelines news

Show

From To
FDA Eliminates REMS for HIV Drug Truvada and its Generics

The US Food and Drug Administration (FDA) announced late Monday that it would eliminate the risk evaluation and mitigation strategy (REMS) for Gilead's Truvada (emtricitabine/tenofovir disoproxil fumarate) and its four approved generics, which reduce the risk of sexually acquired HIV.

Published
02 July 2019
From
Regulatory Focus
USPSTF PrEP Recommendation a Major Step Forward, but Not a Silver Bullet

The new ruling theoretically means patients will be able to access the drug without being exposed to high costs—or any costs, for that matter. However, it’s unclear how insurers will implement the USPSTF’s recommendations. That’s because, while on paper their requirements are straightforward, there are a number of variables available to insurers that might impact patients’ ability to access the drug.

Published
01 July 2019
From
Contagion Live
Advocates find Harris PrEP bill lacking

Senator Kamala Harris (D-California) last week introduced legislation that would expand access to PrEP by requiring public and private health insurers to cover it and funding a grant program for uninsured individuals. But some advocates say Harris needs to work with the community to develop a better plan.

Published
01 July 2019
From
Bay Area Reporter
U.S. Reps to Gilead: Did your donation of free HIV prevention drug Truvada have strings attached?

In May, Gilead pledged to donate 2.4 million bottles of its HIV drug Truvada to the U.S. government’s effort to eradicate the disease, partly by preventing new infections. But now Gilead is facing accusations that its largesse may have suspicious underpinnings. The House Oversight Committee’s chairman, Rep. Elijah E. Cummings (D-MD), and three colleagues sent a letter to Gilead demanding details about what led to the company’s generous offer.

Published
01 July 2019
From
FiercePharma
England: More than a quarter of sexual health clinics closed to new PrEP trial places

Despite a promised expansion of 13,000 places, Seema Kennedy has revealed that 38 of the 147 sites taking part in the PrEP Impact Trial are closed to some new recruits to the trial.

Published
01 July 2019
From
Pharmaceutical Journal
Nine HIV diagnoses in men on PrEP waiting list, Manchester

Nine gay men are known to have seroconverted since being put on a waiting list for pre-exposure prophylaxis (PrEP) at a single Manchester clinic, Dr Sally Jewsbury

Published
01 July 2019
By
Roger Pebody
US: Federal Guidelines May Inadvertently Restrict Women’s Access to Effective HIV Protection

Restrictive recommendations for pre-exposure prophylaxis (or PrEP) issued by the Centers for Disease Control and Prevention (CDC) systematically disqualified nearly all women at risk for HIV and/or motivated to use the medication, researchers at the Yale School of Public Health and George Washington University have found.

Published
25 June 2019
From
Yale School of Public Health
Desperate patients turn to buyers clubs

What do you do when the NHS won’t buy the treatment you need?

Published
25 June 2019
From
The Economist (free registration required)
US: Senate Bill Proposes Expansion of PrEP Access

A bill introduced by Senator Kamala Harris (D-CA) Thursday, the PrEP Access and Coverage Act, would expand access to pre-exposure prophylaxis (PrEP), medications that can reduce the risk of HIV infection by up to 92%.

Published
25 June 2019
From
Pharmacy Times
The Slow Rollout Of PrEP Is Denying Gay Men Their Right To Human Dignity

Gay men are already a socially marginalised and stigmatised group – their health can no longer continue to be sacrificed, National AIDS Trust's Yused Azad writes

Published
24 June 2019
From
Huffington Post

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.